Chinese Journal of Dermatology ›› 2019, Vol. 52 ›› Issue (2): 77-80.doi: 10.3760/cma.j.issn.0412-4030.2019.02.001
• Special Article • Next Articles
WANG Gang
Received:
2018-11-26
Revised:
2019-01-04
Online:
2019-02-15
Published:
2019-01-29
Contact:
WANG Gang
E-mail:xjwgang@fmmu.edu.cn
WANG Gang. Main adverse reactions in biological agents in dermatology and their strategies[J].Chinese Journal of Dermatology, 2019, 52(2): 77-80.
[1] | Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies[J]. Int J Dermatol, 2018,doi: 10.1111/ijd.14246. |
[2] | Kamata M, Tada Y. Safety of biologics in psoriasis[J]. J Dermatol, 2018,45:279⁃286. doi: 10.1111/1346⁃8138.14096. |
[3] | Cannizzaro MV, Franceschini C, Esposito M, et al. Hepatitis B reactivation in psoriasis patients treated with anti⁃TNF agents: prevention and management[J]. Psoriasis (Auckl), 2017,7(1):35⁃40. doi: 10.2147/PTT.S108209. |
[4] | Fabbrocini G, Napolitano M, Megna M, et al. Treatment of atopic dermatitis with biologic drugs[J]. Dermatol Ther (Heidelb), 2018,8(4):527⁃538. doi: 10.1007/s13555⁃018⁃0258⁃x. |
[5] | Kocatürk E, Zuberbier T. New biologics in the treatment of urticaria[J]. Curr Opin Allergy Clin Immunol, 2018,18(5):425⁃431. doi:10.1097/ACI.0000000000000466. |
[6] | Robinson JV, James AL. Some observations on the effects produced in white mice following the injection of certain suspensions of corroding bacilli[J]. Br J Exp Pathol, 1975,56(1):14⁃16. |
[7] | Kluger HM, Chiang V, Mahajan A, et al. Long⁃term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase ii trial[J]. J Clin Oncol, 2019,37(1):52⁃60. doi: 10.1200/JCO.18.00204. |
[8] | Fathi R, Armstrong AW. The role of biologic therapies in dermatology[J]. Med Clin North Am, 2015,99(6):1183⁃1194. doi: 10.1016/j.mcna.2015.07.008. |
[9] | 李峰, 晋红中. 119例英夫利西单抗不良反应的文献分析[J]. 中国药物警戒, 2016,13(4):229⁃232. |
[10] | 代菲, 储文功. 70例阿达木单抗注射液的药物不良反应报告分析[J]. 中国新药杂志, 2013(7):853⁃856. |
[11] | 张瑞丽, 朱小红, 华海康, 等. 阿达木单抗治疗重度银屑病14例临床疗效及安全性观察[J]. 中华皮肤科杂志, 2018,51(8):604⁃606. doi: 10.3760/cma.j.issn.0412⁃4030.2018.08.012. |
[12] | Cui L, Chen R, Subedi S, et al. Efficacy and safety of biologics targeting IL⁃17 and IL⁃23 in the treatment of moderate⁃to⁃severe plaque psoriasis: a systematic review and meta⁃analysis of randomized controlled trials[J]. Int Immunopharmacol, 2018,62:46⁃58. doi: 10.1016/j.intimp.2018.06.020. |
[13] | Fu M, Wang G. Biologic treatments for psoriasis in China: current status and potential tuberculosis and hepatitis B virus risks[J]. Int J Dermatol Venereol, 2018,1(2):99⁃106. |
[14] | Bissonnette R, Luger T, Thaçi D, et al. Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate⁃to⁃severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)[J]. J Eur Acad Dermatol Venereol, 2018,32(9):1507⁃1514. doi:10.1111/jdv. 14878. |
[15] | Tonacci A, Billeci L, Pioggia G, et al. Omalizumab for the treatment of chronic idiopathic urticaria: systematic review of the literature[J]. Pharmacotherapy, 2017,37(4):464⁃480. doi: 10.1002/phar.1915. |
[16] | Ariëns LFM, Bakker DS, van der Schaft J, et al. Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy[J]. Ther Adv Chronic Dis, 2018,9(9):159⁃170. doi:10.1177/204062 2318773686. |
[17] | Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases[J]. Annu Rev Med, 2004,55:477⁃503. doi: 10.1146/annurev.med.55.091902.10 4249. |
[18] | 朱昆, 于倩, 郭义明, 等. 再次输注利妥昔单抗致严重不良反应1例[J]. 武警医学, 2018, 29(11):1091⁃1093. |
[19] | 梁佳. 利妥昔单抗致心律失常1例[J]. 医药导报, 2016,35(8):900⁃900. doi: 10.3870/j.issn.1004⁃0781.2016.08.024. |
[20] | 杨勇, 罗宸婧, 杨阳. 利妥昔单抗注射液致间质性肺疾病合并呼吸衰竭案例分析[J]. 中国医药, 2017,12(8):1161⁃1163. doi: 10.3760/cma.j.issn.1673⁃4777.2017.08.011. |
[21] | 李文静, 王志伟, 赵田华, 等. 小剂量利妥昔单抗治疗免疫性血小板减少症临床效果观察[J]. 解放军医药杂志, 2018,30(9):80⁃83. doi: 10.3969/j.issn.2095⁃140X.2018.09.022. |
[22] | Pottinger E, Woolf RT, Exton LS, et al. Exposure to biological therapies during conception and pregnancy: a systematic review[J]. Br J Dermatol, 2018,178(1):95⁃102. doi: 10.1111/bjd.15802. |
[23] | Dogra S, Mahajan R. Biologics in pediatric psoriasis⁃efficacy and safety[J]. Expert Opin Drug Saf, 2018,17(1):9⁃16. doi: 10.1080/14740338.2018.1391787. |
[24] | IMGJ B, MMB S, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis[J]. JAMA Dermatol, 2017,153(11):1147⁃1157. doi: 10.1001/jamadermatol.2017.3029. |
[25] | Wong PKK, Bagga H, Barrett C, et al. A practical approach to the use of conventional synthetic, biologic and targeted synthetic disease modifying anti⁃rheumatic drugs for the treatment of inflammatory arthritis in patients with a history of malignancy[J]. Curr Rheumatol Rep, 2018,20(10):64. doi: 10.1007/s11926⁃018⁃0774⁃9. |
[1] | . Expression of ubiquitin-conjugating enzyme E2S in malignant melanoma and its effect on the biological behavior of melanoma cells [J]. Chinese Journal of Dermatology, 2019, 52(8): 542-547. |
[2] | Liang Yuan, Liu Lingling, Wang Shan, Zhao Zuotao, Ma Lin, Xiang Xin, Gu Heng, Chen Kun, Wang Hua, Yi Hong, Chen Jinping, Zhang Jintao, Yao Zhirong, Guo Yifeng, Chen Ji, Cheng Ying, Zhu Xuejun. Efficacy and safety of 0.03% tacrolimus ointment in the long-term intermittent maintenance treatment of atopic dermatitis in children: a multicenter randomized controlled clinical trial [J]. Chinese Journal of Dermatology, 2019, 52(8): 519-524. |
[3] | Su Beibei, Gan Quan, Gan Caibin. Effects of metformin on inflammatory status and phosphorylated Stat3 expression in lesions of a psoriasis?like mouse model [J]. Chinese Journal of Dermatology, 2019, 52(7): 475-480. |
[4] | Chen Yiwen, Su Ting, Su Zhonglan. Association between psoriasis and STAT3 [J]. Chinese Journal of Dermatology, 2019, 52(7): 502-505. |
[5] | Ping Xiaofang, Cui Ximei, Chen Wei, Xing Weibin. Inhibitory effect of luteolin on the growth, migration and vasculogenic mimicry formation of a melanoma cell line B16 [J]. Chinese Journal of Dermatology, 2019, 52(6): 401-407. |
[6] | Qin Hui, Zheng Jie. FTY720 ameliorates psoriasis by inhibiting infiltration of skin Interleukin 17-producing γδT cells [J]. Chinese Journal of Dermatology, 2019, 52(6): 395-400. |
[7] | Wang Liwei, Luo Lingling, Cui Pan′gen, Li Min. Relationship between intestinal flora and psoriasis [J]. Chinese Journal of Dermatology, 2019, 52(5): 357-360. |
[8] | Hu Yu, Chen Min, Gu Heng. MicroRNA and lncRNA in psoriasis [J]. Chinese Journal of Dermatology, 2019, 52(5): 350-353. |
[9] | Pan Jiaxu, Zhou Jing. NF?κB signaling pathway in psoriasis [J]. Chinese Journal of Dermatology, 2019, 52(5): 361-363. |
[10] | Xu Yanfeng, Du Weiping, Luo Zhicheng, Shen Hailian. Efficacy of desloratadine citrate disodium in the treatment of chronic urticaria and its effect on serum interleukin-23, interleukin-33 and PARC/CCL-18 [J]. Chinese Journal of Dermatology, 2019, 52(5): 337-339. |
[11] | Zeng Jingxin, Tian Xin, Zhu Huilan, Zhang Xibao, Lin Ling, Zhang Lidan, Liu Weiyu, Luo Quan . Expression of miRNA-148a-3p in CD4+ T lymphocytes in peripheral blood of patients with psoriasis vulgaris and its clinical significance [J]. Chinese Journal of Dermatology, 2019, 52(4): 231-235. |
[12] | Luo Jincheng, Chen Shuguang, Liu Wenying, Xu Yan, Song Zhiqiang. Effect of autologous whole blood injections on expression of FcεRⅠ and CD63 on basophils in patients with refractory chronic spontaneous urticaria and positive autologous serum skin test [J]. Chinese Journal of Dermatology, 2019, 52(4): 241-247. |
[13] | Committee on Psoriasis, Chinese Society of Dermatology. Guideline for the diagnosis and treatment of psoriasis in China (2018 simplified edition) [J]. Chinese Journal of Dermatology, 2019, 52(4): 223-230. |
[14] | Wang Mengjiao, Cui Aili, Jin Chenglong, Fang Yuhui, Jin Zhehu . Effects of RGD peptide-modified fenretinide liposomes on proliferation, apoptosis and migration of malignant melanoma cells [J]. Chinese Journal of Dermatology, 2019, 52(3): 182-188. |
[15] | Working Committee on Standardized Diagnosis and Treatment, China Dermatologist Association, Dermatological Surgical Equipment Group and Skin Phototherapy Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Clinical application of home narrow band ultraviolet B phototherapy: an expert consensus statement [J]. Chinese Journal of Dermatology, 2019, 52(3): 156-161. |
|